SEC Filing Summary for Axsome Therapeutics, Inc. - Form 4 Filing

This filing details a transaction by Herriot Tabuteau, CEO and 10% owner of Axsome Therapeutics, Inc. On April 21, 2026, Tabuteau was granted 24,081 Performance Stock Units (PSUs) with a transaction value of $0. These PSUs are contingent on achieving certain sales and commercial launch milestones and require continued service from Tabuteau. Each PSU represents a right to one share of Axsome's common stock. The PSUs will vest upon the achievement of these milestones, subject to Tabuteau's continued employment. The post-transaction ownership of these PSUs is 24,081 shares.